Comparison of a recombinant DNA hepatitis B vaccine alone or in combination with hepatitis B immune globulin for the prevention of perinatal acquisition of hepatitis B carriage
β Scribed by Y. Poovorawan; S. Sanpavat; W. Pongpunlet; S. Chumdermpadetsuk; P. Sentrakul; S. Chitinand; R. Sakulramrung; Y. Tannirundorn
- Book ID
- 119150801
- Publisher
- Elsevier Science
- Year
- 1990
- Tongue
- English
- Weight
- 381 KB
- Volume
- 8
- Category
- Article
- ISSN
- 0264-410X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
One hundred eleven newborn infants born of Spanish hepatitis B surface antigen (HBsAg) carrier mothers were consecutively assigned to one of three treatment groups. Group A was treated with three or four doses of hepatitis B immune globulin (HBIG) in one of three different schedules. Group B receive
A randomized double-blind, placebo-controlled efficacy trial of hepatitis B immune globulin (HBIG) for prevention of the mother-to-infant transmitted HBsAg carrier state was conducted in Taiwan where the carrier rate in the general population is 15 to 20%. HBIG was given immediately after birth to i
## Abstract In some patients with chronic liver disease induced by hepatitis B virus, viral DNA is known to persist in low concentration in serum after seroconversion to hepatitis B surface antibodyβpositivity. This phenomenon has, however, not been documented in asymptomatic black African carriers